Fees are a weakness here. The strategy's lofty fees are a high hurdle to clear, as it is priced within the highest quintile among peers.
Rydex Biotechnology C RYCFX
- NAV / 1-Day Return 55.48 / +0.40 %
- Total Assets 114.7 Mil
-
Adj. Expense Ratio
2.390%
- Expense Ratio 2.390%
- Distribution Fee Level High
- Share Class Type Level Load
- Category Health
- Investment Style Mid Growth
- Min. Initial Investment 2,500
- Status Open
- TTM Yield —
- Turnover 51%
USD | NAV as of Jul 26, 2024 | 1-Day Return as of Jul 26, 2024, 10:17 PM GMT+0
Morningstar’s Analysis RYCFX
Will RYCFX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings —
|
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
|---|---|---|---|
AbbVie Inc | 8.08 | 8.4 Mil | Healthcare |
Amgen Inc | 6.15 | 6.4 Mil | Healthcare |
Regeneron Pharmaceuticals Inc | 4.96 | 5.2 Mil | Healthcare |
Vertex Pharmaceuticals Inc | 4.21 | 4.4 Mil | Healthcare |
Moderna Inc | 3.69 | 3.8 Mil | Healthcare |
Gilead Sciences Inc | 3.59 | 3.7 Mil | Healthcare |
Corteva Inc | 3.36 | 3.5 Mil | Basic Materials |
AstraZeneca PLC ADR | 3.33 | 3.5 Mil | Healthcare |
Biogen Inc | 3.11 | 3.2 Mil | Healthcare |
Alnylam Pharmaceuticals Inc | 2.31 | 2.4 Mil | Healthcare |